A Phase 3 interventional study of Gabapentin Extended Release and Placebo in Hot Flashes, sponsored by Depomed. Completed at 66 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-05-01.
Sponsored by Depomed · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing gabapentin in Hot Flashes — none open to participants now, none under way, none of them phase 3. Gabapentin · Hot Flashes.
Among the 11 studies testing gabapentin in Hot Flashes, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2010, is one of 6 in phase 3, and was the 9th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 11 studies testing gabapentin in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 600 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 160 across the 10 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 11 have an industry lead sponsor. The 7 most frequent:
Depomed is the lead sponsor of 14 studies on the registry; none are open to participants now.
Depomed has 4 studies filed under Hot Flashes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing gabapentin in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of Gabapentin that is being studied for the treatment of Hot Flashes/Hot Flushes in postmenopausal women
The primary study objective is to assess the efficacy of G-ER dosed at 1800mg daily (600mg AM, 1200mg PM), compared to placebo in reducing the average daily frequency and severity score of moderate to severe hot flashes in postmenopausal women at weeks 4 \& 12 of the efficacy treatment period, compared with baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other inclusions apply.
Exclusion Criteria:
Other exclusions apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active treatment
Drug: Gabapentin Extended Release
Placebo
Drug: Placebo
Gabapentin ER 1800mg daily
Sugar pill
G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.
G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline.
Time frame: Baseline, Week 4, and Week 12
G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period, Compared With Baseline.
G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as "Mild" (1), "Moderate" (2), and "Severe" (3)) at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline.
Time frame: Baseline, Week 4, and Week 12
G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.
G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 24 of the efficacy treatment period compared with Baseline.
Time frame: Baseline, Week 24
G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline.
G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as "Mild" (1), "Moderate" (2), and "Severe" (3)) at Week 24 of the efficacy treatment period compared with Baseline.
Time frame: Baseline, Week 24
Patient Global Impression of Change (PGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.
Proportion of patients who were categorized as "very much" or "much improved" for PGIC at Week 12 and Week 24. Scale range is 6 categories: "minimum value = very much worse" to "maximum value = very much improved".
Time frame: Week 12 and Week 24
Clinical Global Impression of Change (CGIC) Scales at Weeks 12 and 24 of the Efficacy Treatment Period.
Proportion of patients who were categorized as "very much" or "much improved" in CGIC at Week 12 and Week 24. Scale range is 6 categories: "minimum value = very much worse" to "maximum value = very much improved".
Time frame: Week 12 and Week 24
Percent of Patients With 75% or Greater Reduction in Average Daily Frequency of Moderate to Severe Hot Flashes
Time frame: Baseline, Week 12, and Week 24
Percent of Patients With 75% or Greater Reduction in Average Daily Severity Score of Moderate to Severe Hot Flashes
Time frame: Baseline, Week 12, and Week 24
Change From Baseline to Weeks 4, Week 12, and Week 24 in Average Daily Sleep Interference Score.
Sleep Interference Score Range: Minimum value = 0, maximum value = 10 Lower scores indicate better outcome (ie, less interference)
Time frame: Baseline, Week 4, Week 12, and Week 24
Changes From Baseline in Sleep Quality Scores, Measured by the Insomnia Severity Index (ISI) to Week 4, Week 12, and Week 24 of the Efficacy Treatment Period.
Insomnia Severity Index (ISI) scored on 4-point Likert-scales ('0' not at all - '4' extremely) for 7 sub-categories. Final score is sum of each sub-category generating a total sleep quality score (0-28). Minimum value = 0, maximum value = 28 (Lower scores indicate better outcome (ie, less severity)).
Time frame: Baseline, Week 4, Week 12, and Week 24
Changes From Baseline in Quality of Life Scores, Measured by the Menopause-Specific Quality of Life Questionnaire (MENQOL) to Weeks, 4, 12, 24 of the Efficacy Treatment Period.
4 sub-categories each scored individually: Minimum value = 1, maximum value = 8. Overall summary score was mean of the 4 sub-category scores (minimum = 1 and maximum = 8). Lower scores indicate better outcome (ie, less severity)
Time frame: Baseline, Week 4, Week 12, and Week 24
Safety of G-ER Measuring Columbia-Suicide Severity Rating Scale (C-SSRS).
Columbia-Suicide Severity Rating Scale (C-SSRS). Subjects were classified as 0=no suicidal ideation or 1=suicidal ideation. Outcome Measure is number of participants with or without suicidal ideation. Higher counts without suicidal ideation = better outcome.
Time frame: Week 4, Week 12, Week 24/Early Termination, Week 28
| Milestone | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Started | 300 | 295 |
| Completed | 206 | 191 |
| Not completed | 94 | 104 |
| Withdrew: Adverse event | 49 | 35 |
| Withdrew: Lack of efficacy | 12 | 15 |
| Withdrew: Protocol violation | 7 | 13 |
| Withdrew: Lost to follow-up | 10 | 6 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Withdrawal by subject | 12 | 28 |
| Withdrew: Reasons not specified | 4 | 6 |
G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline.
| hot flashes | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Baseline LOCF Average Daily Frequency at Week 4 | -6.72 (-7.24 to -6.19) | -5.01 (-5.54 to -4.49) |
| Baseline LOCF Average Daily Frequency at Week 12 | -7.64 (-8.21 to -7.07) | -6.50 (-7.07 to -5.94) |
G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as "Mild" (1), "Moderate" (2), and "Severe" (3)) at Week 4 of the efficacy treatment period compared with Baseline and at Week 12 of the efficacy treatment period compared with Baseline.
| scores on a scale | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Baseline LOCF Average Daily Severity at Week 4 | -0.42 (-0.51 to -0.33) | -0.22 (-0.31 to -0.13) |
| Baseline LOCF Average Daily Severity at Week 12 | -0.65 (-0.77 to -0.52) | -0.46 (-0.58 to -0.34) |
G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily frequency of moderate to severe hot flashes in post menopausal women at Week 24 of the efficacy treatment period compared with Baseline.
| hot flashes | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline. | -8.99 (-9.71 to -8.27) | -7.91 (-8.62 to -7.19) |
G-ER dosed at 1800mg daily(600mg AM, 1200mg PM), compared with placebo in reducing the average daily severity score of moderate to severe hot flashes in post menopausal women (score defined as "Mild" (1), "Moderate" (2), and "Severe" (3)) at Week 24 of the efficacy treatment period compared with Baseline.
| scores on a scale | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Severity Score of Moderate to Severe Hot Flashes at Week 24 of the Efficacy Treatment Period, Compared With Baseline. | -0.86 (-1.03 to -0.69) | -0.64 (-0.81 to -0.47) |
Proportion of patients who were categorized as "very much" or "much improved" for PGIC at Week 12 and Week 24. Scale range is 6 categories: "minimum value = very much worse" to "maximum value = very much improved".
| Participants | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Baseline LOCF Proportion at Week 12 | 173 | 130 |
| Baseline LOCF Proportion at Week 24 | 156 | 114 |
Proportion of patients who were categorized as "very much" or "much improved" in CGIC at Week 12 and Week 24. Scale range is 6 categories: "minimum value = very much worse" to "maximum value = very much improved".
| Participants | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Baseline LOCF Proportion at Week 12 | 173 | 122 |
| Baseline LOCF Proportion at Week 24 | 159 | 124 |
| Participants | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Baseline LOCF Proportion at Week 12 | 125 | 101 |
| Baseline LOCF Proportion at Week 24 | 146 | 122 |
| Participants | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Baseline LOCF Average Daily Score at Week 12 | 48 | 36 |
| Baseline LOCF Average Daily Score at Week 24 | 62 | 48 |
Sleep Interference Score Range: Minimum value = 0, maximum value = 10 Lower scores indicate better outcome (ie, less interference)
| units on a scale | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Change from Baseline to Week 4: LOCF daily rating | -2.67 (-3.00 to -2.33) | -1.31 (-1.64 to -0.97) |
| Change from Baseline to Week 12: LOCF daily rating | -3.09 (-3.47 to -2.71) | -2.17 (-2.56 to -1.79) |
| Change from Baseline to Week 24: LOCF daily rating | -3.15 (-3.56 to -2.75) | -2.20 (-2.60 to -1.80) |
Insomnia Severity Index (ISI) scored on 4-point Likert-scales ('0' not at all - '4' extremely) for 7 sub-categories. Final score is sum of each sub-category generating a total sleep quality score (0-28). Minimum value = 0, maximum value = 28 (Lower scores indicate better outcome (ie, less severity)).
| scores on a scale | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Change from Baseline to Week 4: LOCF ISI rating | -6.47 (-7.67 to -5.82) | -4.13 (-5.04 to -3.21) |
| Change from Baseline to Week 12: LOCF ISI rating | -7.02 (-7.96 to -6.09) | -5.17 (-6.10 to -4.25) |
| Change from Baseline to Week 24: LOCF ISI rating | -6.71 (-7.65 to -5.77) | -4.95 (-5.88 to -4.01) |
4 sub-categories each scored individually: Minimum value = 1, maximum value = 8. Overall summary score was mean of the 4 sub-category scores (minimum = 1 and maximum = 8). Lower scores indicate better outcome (ie, less severity)
| scores on a scale | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Baseline LOCF MENQOL score at Week 4 | -0.91 (-1.06 to -0.77) | -0.71 (-0.85 to -0.57) |
| Baseline LOCF MENQOL score at Week 12 | -1.01 (-1.16 to -0.87) | -0.87 (-1.01 to -0.72) |
| Baseline LOCF MENQOL score at Week 24 | -1.01 (-1.17 to -0.86) | -0.96 (-1.11 to -0.81) |
Columbia-Suicide Severity Rating Scale (C-SSRS). Subjects were classified as 0=no suicidal ideation or 1=suicidal ideation. Outcome Measure is number of participants with or without suicidal ideation. Higher counts without suicidal ideation = better outcome.
| Participants | Gabapentin Extended Release | Placebo |
|---|---|---|
| Patients Taking C-SSRS at Week 4 — With Suicidal Ideation | 0 | 0 |
| Patients Taking C-SSRS at Week 4 — Without Suicidal Ideation | 260 | 257 |
| Patients Taking C-SSRS at Week 12 — With Suicidal Ideation | 1 | 0 |
| Patients Taking C-SSRS at Week 12 — Without Suicidal Ideation | 224 | 215 |
| Patients Taking C-SSRS at Week 24/EarlyTermination — With Suicidal Ideation | 0 | 1 |
| Patients Taking C-SSRS at Week 24/EarlyTermination — Without Suicidal Ideation | 271 | 266 |
| Patients Taking C-SSRS at Week 28 — With Suicidal Ideation | 1 | 0 |
| Patients Taking C-SSRS at Week 28 — Without Suicidal Ideation | 256 | 243 |
Collected over Adverse events collected for a total of 28-42 weeks: from after signing the informed consent to the end of the study (Week 28).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| G-ER 1800 mg | — | 4/300 (1.3%) | 102/300 (34%) |
| Sugar Pill | — | 7/295 (2.4%) | 53/295 (18%) |
| Event | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/300 | 1/295 |
| PalpitationsCardiac disorders | 0/300 | 1/295 |
| Acute sinusitisInfections and infestations | 0/300 | 1/295 |
| Bronchitis acuteInfections and infestations | 0/300 | 1/295 |
| Pneumonia primary atypicalInfections and infestations | 0/300 | 1/295 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/300 | 1/295 |
| Haemorrhagic strokeNervous system disorders | 0/300 | 1/295 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/300 | 1/295 |
| HypertensionVascular disorders | 0/300 | 1/295 |
| AnaemiaBlood and lymphatic system disorders | 1/300 | 0/295 |
| Event | G-ER 1800 mg | Sugar Pill |
|---|---|---|
| DizzinessNervous system disorders | 38/300 | 10/295 |
| HeadacheNervous system disorders | 28/300 | 24/295 |
| SomnolenceNervous system disorders | 18/300 | 8/295 |
| Upper respiratory tract infectionInfections and infestations | 18/300 | 11/295 |
Intent-to-treat (ITT) Population
| Age, Continuous(years) | G-ER 1800 mg | Sugar Pill | Total |
|---|---|---|---|
| Mean | 54.0 ± 6.1 | 54.0 ± 6.0 | 54.0 ± 6.1 |
| Age, Customized(participants) | G-ER 1800 mg | Sugar Pill | Total |
|---|---|---|---|
| < 65 years | 280 | 282 | 562 |
| >=65 years | 19 | 12 | 31 |
| Sex: Female, Male(Participants) | G-ER 1800 mg | Sugar Pill | Total |
|---|---|---|---|
| Female | 299 | 294 | 593 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | G-ER 1800 mg | Sugar Pill | Total |
|---|---|---|---|
| White | 215 | 197 | 412 |
| Black | 74 | 82 | 156 |
| Asian | 1 | 2 | 3 |
| Hispanic | 9 | 9 | 18 |
| Other | 0 | 4 | 4 |
| Frequency of hot flashes(hot flashes) | G-ER 1800 mg | Sugar Pill | Total |
|---|---|---|---|
| Mild | 1.5 ± 2.8 | 1.5 ± 3.3 | 1.5 ± 3.1 |
| Moderate | 6.4 ± 5.3 | 6.1 ± 4.9 | 6.3 ± 5.1 |
| Severe | 7.1 ± 10.6 | 6.5 ± 5.4 | 6.8 ± 8.4 |
The record gives a start of Aug 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gabapentin
Depomed